Another CD47 targeting bsAB, IBI322, with a dual specificity for CD47 and PD-L1 [122], is also being tested in several clinical trials in patients with advanced malignant tumors (NCT04328831, NCT04912466, NCT04338659) and hematologic malignancies (NCT04795128), but no clinical data has been reported yet. This evidence concerns the gene CD47 and cancer.